MA28855B1 - Procédé de fabrication de dérivés d'amines optiquement actifs - Google Patents

Procédé de fabrication de dérivés d'amines optiquement actifs

Info

Publication number
MA28855B1
MA28855B1 MA29745A MA29745A MA28855B1 MA 28855 B1 MA28855 B1 MA 28855B1 MA 29745 A MA29745 A MA 29745A MA 29745 A MA29745 A MA 29745A MA 28855 B1 MA28855 B1 MA 28855B1
Authority
MA
Morocco
Prior art keywords
optically active
active amino
amino derivatives
producing optically
producing
Prior art date
Application number
MA29745A
Other languages
English (en)
Inventor
Shinichi Urayama
Eigo Mutou
Atsushi Inagaki
Takashi Okada
Shigeharu Sugisaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36059992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28855(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA28855B1 publication Critical patent/MA28855B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
MA29745A 2004-09-13 2007-03-09 Procédé de fabrication de dérivés d'amines optiquement actifs MA28855B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004265307 2004-09-13

Publications (1)

Publication Number Publication Date
MA28855B1 true MA28855B1 (fr) 2007-09-03

Family

ID=36059992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29745A MA28855B1 (fr) 2004-09-13 2007-03-09 Procédé de fabrication de dérivés d'amines optiquement actifs

Country Status (32)

Country Link
US (4) US8097737B2 (fr)
EP (2) EP1792899B1 (fr)
JP (2) JP5127228B2 (fr)
KR (1) KR101298335B1 (fr)
CN (2) CN102516211A (fr)
AR (1) AR050737A1 (fr)
AU (1) AU2005283521B2 (fr)
BR (1) BRPI0515170A (fr)
CA (2) CA2764314C (fr)
CR (2) CR8975A (fr)
EC (1) ECSP077317A (fr)
ES (1) ES2485890T3 (fr)
GE (1) GEP20094725B (fr)
GT (2) GT200500257AA (fr)
HN (1) HN2005000548A (fr)
IL (2) IL181462A (fr)
MA (1) MA28855B1 (fr)
MX (1) MX2007002822A (fr)
MY (2) MY158073A (fr)
NO (1) NO20071866L (fr)
NZ (1) NZ553562A (fr)
PA (1) PA8645701A1 (fr)
PE (3) PE20130154A1 (fr)
PH (1) PH12012501172A1 (fr)
RU (1) RU2385318C2 (fr)
SA (1) SA05260347A (fr)
SG (1) SG151330A1 (fr)
TW (1) TWI400220B (fr)
UA (1) UA95598C2 (fr)
UY (1) UY29118A1 (fr)
WO (1) WO2006030739A1 (fr)
ZA (1) ZA200701724B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5450056B2 (ja) * 2007-03-19 2014-03-26 武田薬品工業株式会社 アリルアミン不斉水素化法
WO2008150953A1 (fr) * 2007-05-30 2008-12-11 Dr. Reddy's Laboratories Ltd. Procédé de préparation de rameltéon et substances apparentées
EP2098519A1 (fr) * 2007-05-31 2009-09-09 Teva Pharmaceutical Industries Ltd. Procédé de synthèse du rameltéon et ses intermédiaires
WO2009060318A2 (fr) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Formes polymorphes de rameltéon et leurs procédés de préparation
CN101531647B (zh) * 2008-03-13 2012-10-31 常州亚邦制药有限公司 (±)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺的拆分方法
AU2009272802A1 (en) * 2008-07-14 2010-01-21 Lek Pharmaceuticals D.D. Synthesis of 6,7-dihydro-1H-indeno[5,4-b]furan-8(2H)-one as intermediate in the preparation of ramelteon
WO2010045565A1 (fr) * 2008-10-16 2010-04-22 Teva Pharmaceutical Industries Ltd. Procédé de synthèse du ramelteon et de ses intermédiaires
WO2010092107A1 (fr) 2009-02-12 2010-08-19 Lek Pharmaceuticals D.D. Synthèse de (s)-n-[2-(1,6,7,8-tétrahydro-2h-indéno-[5,4-b]furan-8-yl)éthyl]propionamide
CN101824012B (zh) * 2009-03-02 2011-12-07 四川大学 2-(1,6,7,8-四氢-2H-茚并-[5,4-b]呋喃-8-基)乙腈及其制备方法和用途
WO2010103553A1 (fr) 2009-03-10 2010-09-16 Industriale Chimica S.R.L. Procédé de préparation du rameltéon
EP2243775A1 (fr) 2009-04-07 2010-10-27 LEK Pharmaceuticals d.d. Synthèse de 1-(2,3-dihydrobenzofuran-4-YL)éthanone en tant qu'intermédiaire dans la préparation de rameltéon
WO2011027323A1 (fr) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Procédé de préparation de ramelteon
WO2011027319A1 (fr) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Procédé de préparation d'un produit intermédiaire de rameltéon
CN101648931B (zh) * 2009-09-21 2012-05-09 四川大学 一种3-(2,3-二氢苯并呋喃-5-基)-丙酸的制备方法
CN101665477B (zh) * 2009-09-21 2012-05-09 四川大学 (e)-3-(苯并呋喃-5-基)丙烯酸酯类化合物、其制备方法和用途
EP2483258A1 (fr) 2009-09-29 2012-08-08 Lonza Ltd. Procédé de préparation de 1,2,6,7-tétrahydro-8h-indeno[5,4-b]furan-8-one
WO2012035303A2 (fr) 2010-09-17 2012-03-22 Cipla Limited Et Al Nouveau procédé de synthèse du ramelteon et intermédiaires clés pour la synthèse du ramelteon
CN103664849B (zh) * 2012-08-31 2017-03-29 上海阳帆医药科技有限公司 制备2‑(1,6,7,8‑四氢‑2H‑茚并[5,4‑b]呋喃‑8‑亚基乙胺的方法
CN102924410A (zh) * 2012-10-29 2013-02-13 华润赛科药业有限责任公司 一种雷美替胺的制备方法及其中间体
CN103396387A (zh) * 2013-08-07 2013-11-20 安徽联创药物化学有限公司 雷美替胺中间体的制备方法
CN105277628B (zh) * 2014-07-07 2017-05-31 南京长澳医药科技有限公司 通过高效液相色谱法分离测定雷美替胺及其杂质的方法
CN104402848B (zh) * 2014-09-22 2017-02-08 珠海联邦制药股份有限公司 雷美替胺中的杂质化合物的制备方法及制备的标准品
CN105622557B (zh) * 2014-11-05 2018-12-04 上海医药工业研究院 雷美替胺中间体及其制备方法
KR102359229B1 (ko) 2020-04-16 2022-02-07 제이투에이치바이오텍 (주) 라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물
CN115477628A (zh) * 2022-10-17 2022-12-16 江苏海悦康医药科技有限公司 一种雷美替胺二聚体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
WO1996026931A1 (fr) 1995-03-02 1996-09-06 Sankyo Company, Limited Derives de thiazolidinone optiquement actifs
ES2175350T5 (es) * 1996-03-08 2008-12-16 Takeda Pharmaceutical Company Limited Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
JP2884153B2 (ja) 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
EP1199304A1 (fr) * 1997-03-05 2002-04-24 Takeda Chemical Industries, Ltd. Composés bicycliques et composition pharmaceutique contenant un composé tricyclique pour le traitement ou la prévention de troubles de sommeil
JP4242940B2 (ja) 1997-02-13 2009-03-25 高砂香料工業株式会社 光学活性アミン誘導体の製造法
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
EP1100508B8 (fr) * 1998-06-09 2004-01-07 Takeda Chemical Industries, Ltd. Composition pharmaceutique contenant un compose tricyclique et au moin un parmi zolpidem, zopiclone et brotizolam destinee a traiter ou prevenir les troubles du sommeil
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
JP3633895B2 (ja) * 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
AU2002214305A1 (en) 2000-11-17 2002-05-27 Takeda Chemical Industries Ltd. Pharmaceutical preparation containing copolyvidone

Also Published As

Publication number Publication date
PE20130154A1 (es) 2013-02-27
KR20070054200A (ko) 2007-05-28
MY158073A (en) 2016-08-30
AR050737A1 (es) 2006-11-15
UA95598C2 (ru) 2011-08-25
RU2007113811A (ru) 2008-10-20
JP2012116848A (ja) 2012-06-21
US20140066499A1 (en) 2014-03-06
IL207510A (en) 2013-02-28
TW200613239A (en) 2006-05-01
CA2579121A1 (fr) 2006-03-23
US20130079397A1 (en) 2013-03-28
US20120088826A1 (en) 2012-04-12
CA2764314C (fr) 2014-06-17
EP2537842A1 (fr) 2012-12-26
IL181462A0 (en) 2007-07-04
GEP20094725B (en) 2009-07-10
ZA200701724B (en) 2008-08-27
NO20071866L (no) 2007-05-29
NZ553562A (en) 2010-08-27
US8609871B2 (en) 2013-12-17
MY147822A (en) 2013-01-31
BRPI0515170A (pt) 2008-07-08
EP1792899A1 (fr) 2007-06-06
TWI400220B (zh) 2013-07-01
SA05260347A (ar) 2005-12-03
HN2005000548A (es) 2007-04-20
CR20110698A (es) 2012-03-08
GT200500257A (es) 2006-04-17
PE20060662A1 (es) 2006-08-22
AU2005283521B2 (en) 2011-10-13
MX2007002822A (es) 2007-04-23
KR101298335B1 (ko) 2013-08-20
JPWO2006030739A1 (ja) 2008-05-15
RU2385318C2 (ru) 2010-03-27
EP1792899B1 (fr) 2014-07-09
UY29118A1 (es) 2006-06-30
SG151330A1 (en) 2009-04-30
ES2485890T3 (es) 2014-08-14
CN101056867B (zh) 2011-12-07
CR8975A (es) 2007-08-28
JP5127228B2 (ja) 2013-01-23
IL181462A (en) 2011-12-29
ECSP077317A (es) 2007-04-26
JP5615304B2 (ja) 2014-10-29
AU2005283521A1 (en) 2006-03-23
PH12012501172A1 (en) 2014-04-28
CN101056867A (zh) 2007-10-17
EP1792899A4 (fr) 2009-12-16
WO2006030739A1 (fr) 2006-03-23
CN102516211A (zh) 2012-06-27
US20090036521A1 (en) 2009-02-05
US8097737B2 (en) 2012-01-17
CA2764314A1 (fr) 2006-03-23
PA8645701A1 (es) 2006-09-22
PE20081390A1 (es) 2008-10-24
CA2579121C (fr) 2013-07-30
GT200500257AA (es) 2008-07-28

Similar Documents

Publication Publication Date Title
MA28855B1 (fr) Procédé de fabrication de dérivés d'amines optiquement actifs
EP1960157A4 (fr) Procédé de fabrication d'article abrasif structuré
EP1739058A4 (fr) Procédé de fabrication d'une nanostructure carbonée
EP2070633A4 (fr) Procédé d'usinage au laser
EP1925611A4 (fr) Dérivé de diamine optiquement actif et procédé de synthèse dudit dérivé
EP1813677A4 (fr) Procédé de fabrication de substance de base
EP1999200A4 (fr) Procédé de fabrication d'une pellicule poreuse
EP2036966A4 (fr) Phosphores d'oxynitrure à base de sialon et procédé de production de ceux-ci
EP2349962A4 (fr) Procédé de fabrication d'hydrochlorofluorooléfines
EP2096176A4 (fr) Procédé d'obtention de cristal de chlorhydrate d'acide aminé basique
DK2070526T3 (da) Fremgangsmåder til behandling af parkinsons sygdom
EP1739101A4 (fr) PROCÉDÉ DE PRODUCTION D"UN POLYMÈRE alpha-OLÉFINIQUE
EP1683605A4 (fr) Procede d'usinage de piece
EP2080808A4 (fr) Procédé de fabrication d'un l-amino acide
EP2019419A4 (fr) Procédé de fabrication d'une composition polissante
EP2172443A4 (fr) Procédé de fabrication d'une amine optiquement active
EP1767491A4 (fr) Procédé de fabrication d'une nanostructure et nanostructure
EP1911733A4 (fr) Procédé de formation d'unités de maçonnerie
EP1731528A4 (fr) Procédé de fabrication de kératine solubilisée
EP1758154A4 (fr) Procédé de fabrication d'une plaque de silicium et plaque de silicium
EP1885395A4 (fr) Procédé d'augmentation de l'immunigénicité des antigènes de plasmodium
EP1966397A4 (fr) Procédé de réglage de dureté d'un produit en forme de feuille
EP1894910A4 (fr) Procédé servant à produire de l'acide glycolique
EP2116529A4 (fr) Procédé de fabrication d'un amide ou d'un lactame
EP1747212A4 (fr) Procede de fabrication de derives d'acides amines n-sulfones